Matches in SemOpenAlex for { <https://semopenalex.org/work/W2264946596> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2264946596 endingPage "5570" @default.
- W2264946596 startingPage "5570" @default.
- W2264946596 abstract "5570 Background: Nasopharyngeal cancer (NPC) is characterized by a high frequency of distant metastasis and mucositis was a marked problem even when radiotherapy (RT) alone was performed. Considering these characteristics of NPC, alternating chemoradiotherapy (ALT-CRT) may be a useful method of treating NPC because sufficient amount of anti-tumor agents can be administered together with a low frequency of mucositis compared to concurrent chemoradiotherapy (CRT). Methods: The subjects consisted of 20 patients with stage II, 31 patients with stage III and 35 patients with stage IV. Using 6 MV photon, RT was performed at an exposure of 1.8Gy 5 times a week. That is, a total absorbed dose of 36 Gy was irradiated between the basal of skull and supraclavicular fossa. After decreasing the irradiation field, an absorbed dose of 30–34Gy was additionally given thereafter. One course of chemotherapy (CT) consisted of the administration of 5-FU at a dose of 800 mg/m2/24 h for 5 days (days 1–5) and CDDP at a dose of 50 mg/m2/24 h for 2 days (days 6–7), and a total of 3 courses of CT was performed. During the ALT-CRT, CT was performed initially; and 2–3 days after completing the CT, RT was performed for 4 weeks. Thereafter, CT and RT were performed alternately. Results: The scheduled courses of ALT-CRT were completed in 69 (80%) of 86 patients. No severe adverse effects were noted in any other patients. In these 86 patients, the overall 3-year survival rate was 95%, and the progression free survival rate was 82.5% (The median follow up times was 37 months). Conclusions: This method of ALT-CRT yielded higher or at least similar survival rate and lower toxicities than concurrent CRT, and we believed that this method can be used in a controlled clinical trial in the future to compare therapeutic results with those of the Intergroup 0099 Trial. No significant financial relationships to disclose." @default.
- W2264946596 created "2016-06-24" @default.
- W2264946596 creator A5014582936 @default.
- W2264946596 creator A5014718861 @default.
- W2264946596 creator A5018959381 @default.
- W2264946596 creator A5025391863 @default.
- W2264946596 creator A5033780491 @default.
- W2264946596 creator A5039623511 @default.
- W2264946596 creator A5060609402 @default.
- W2264946596 creator A5080516835 @default.
- W2264946596 creator A5081837886 @default.
- W2264946596 creator A5091815932 @default.
- W2264946596 date "2005-06-01" @default.
- W2264946596 modified "2023-10-16" @default.
- W2264946596 title "Excellent treatment results of alternating chemoradiotherapy for nasopharyngeal cancer-A phase II study-" @default.
- W2264946596 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.5570" @default.
- W2264946596 hasPublicationYear "2005" @default.
- W2264946596 type Work @default.
- W2264946596 sameAs 2264946596 @default.
- W2264946596 citedByCount "0" @default.
- W2264946596 crossrefType "journal-article" @default.
- W2264946596 hasAuthorship W2264946596A5014582936 @default.
- W2264946596 hasAuthorship W2264946596A5014718861 @default.
- W2264946596 hasAuthorship W2264946596A5018959381 @default.
- W2264946596 hasAuthorship W2264946596A5025391863 @default.
- W2264946596 hasAuthorship W2264946596A5033780491 @default.
- W2264946596 hasAuthorship W2264946596A5039623511 @default.
- W2264946596 hasAuthorship W2264946596A5060609402 @default.
- W2264946596 hasAuthorship W2264946596A5080516835 @default.
- W2264946596 hasAuthorship W2264946596A5081837886 @default.
- W2264946596 hasAuthorship W2264946596A5091815932 @default.
- W2264946596 hasConcept C121608353 @default.
- W2264946596 hasConcept C126322002 @default.
- W2264946596 hasConcept C141071460 @default.
- W2264946596 hasConcept C146357865 @default.
- W2264946596 hasConcept C151730666 @default.
- W2264946596 hasConcept C2776694085 @default.
- W2264946596 hasConcept C2777968714 @default.
- W2264946596 hasConcept C2778424827 @default.
- W2264946596 hasConcept C2778496288 @default.
- W2264946596 hasConcept C2778997737 @default.
- W2264946596 hasConcept C2989005 @default.
- W2264946596 hasConcept C2992261824 @default.
- W2264946596 hasConcept C509974204 @default.
- W2264946596 hasConcept C530470458 @default.
- W2264946596 hasConcept C71924100 @default.
- W2264946596 hasConcept C86803240 @default.
- W2264946596 hasConceptScore W2264946596C121608353 @default.
- W2264946596 hasConceptScore W2264946596C126322002 @default.
- W2264946596 hasConceptScore W2264946596C141071460 @default.
- W2264946596 hasConceptScore W2264946596C146357865 @default.
- W2264946596 hasConceptScore W2264946596C151730666 @default.
- W2264946596 hasConceptScore W2264946596C2776694085 @default.
- W2264946596 hasConceptScore W2264946596C2777968714 @default.
- W2264946596 hasConceptScore W2264946596C2778424827 @default.
- W2264946596 hasConceptScore W2264946596C2778496288 @default.
- W2264946596 hasConceptScore W2264946596C2778997737 @default.
- W2264946596 hasConceptScore W2264946596C2989005 @default.
- W2264946596 hasConceptScore W2264946596C2992261824 @default.
- W2264946596 hasConceptScore W2264946596C509974204 @default.
- W2264946596 hasConceptScore W2264946596C530470458 @default.
- W2264946596 hasConceptScore W2264946596C71924100 @default.
- W2264946596 hasConceptScore W2264946596C86803240 @default.
- W2264946596 hasIssue "16_suppl" @default.
- W2264946596 hasLocation W22649465961 @default.
- W2264946596 hasOpenAccess W2264946596 @default.
- W2264946596 hasPrimaryLocation W22649465961 @default.
- W2264946596 hasRelatedWork W2084803897 @default.
- W2264946596 hasRelatedWork W2349463750 @default.
- W2264946596 hasRelatedWork W2359686091 @default.
- W2264946596 hasRelatedWork W2359861678 @default.
- W2264946596 hasRelatedWork W2363044209 @default.
- W2264946596 hasRelatedWork W2377166312 @default.
- W2264946596 hasRelatedWork W2390264150 @default.
- W2264946596 hasRelatedWork W2997709950 @default.
- W2264946596 hasRelatedWork W3032219679 @default.
- W2264946596 hasRelatedWork W4247921938 @default.
- W2264946596 hasVolume "23" @default.
- W2264946596 isParatext "false" @default.
- W2264946596 isRetracted "false" @default.
- W2264946596 magId "2264946596" @default.
- W2264946596 workType "article" @default.